Cell lines expressing recombinant transmembrane domain-activated receptor kinases as tools for drug discovery

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Receptor tyrosine kinases (RTKs) are key cancer drug targets.
• Acquired resistance mutations in RTKs limit the efficacy of targeted therapies.
• Development of novel inhibitors necessitates robust cellular models of resistant RTKs.

Purpose of the Study:

• To establish a platform for rapid generation of ligand-independent cellular assays for RTKs.
• To create cellular models for wild-type and drug-resistant RTK mutants.
• To facilitate the discovery of second-generation RTK inhibitors.

Main Methods:

• Utilized artificial transmembrane domains (TMDs) to activate intracellular domains of RTKs (EGFR, MET, KIT).
• Generated transient transfection assays to test RTK autophosphorylation.
• Developed stable cell pools expressing engineered MET and EGFR constructs.
• Validated cell models by comparing sensitivity to reference compounds with established cell lines.

Main Results:

• Successfully generated active, ligand-independent constructs for MET and EGFR, but not KIT.
• Engineered cell pools expressing MET and EGFR showed sensitivity to inhibitors, correlating with natural cell lines.
• Created a panel of clinically relevant MET mutant cell pools for further profiling.
• Demonstrated the platform's utility for generating RTK resistance models.

Conclusions:

• A novel platform enables rapid generation of cellular models for RTKs and their resistance mutants.
• This approach accelerates the development of cellular assays for drug discovery.
• The platform supports the creation of models for studying resistance mechanisms and developing new targeted therapies.